VERAXA Biotech Advances VXA-222 Cancer Program, Expanding Its Oncology Pipeline and IP Portfolio

VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant advancement in its oncology pipeline, moving its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the discovery phase. This development follows the completion of the initial phase of its collaboration with OmniAb, a leader in antibody discovery. The company will now leverage its proprietary antibody engineering, linker, and conjugation technologies to construct the final VXA-222 candidate and conduct the preclinical validation necessary to determine the program's next steps.

VXA-222 employs a novel “AND-gate” approach, designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. This dual-targeting strategy aims to enhance specificity and reduce off-target effects, potentially improving the therapeutic index compared to conventional ADCs. The advancement of VXA-222 underscores VERAXA's commitment to developing next-generation cancer therapies that address the limitations of existing treatments.

In parallel with the VXA-222 progress, VERAXA has filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms. These filings expand the company's intellectual property estate, particularly around antibody conjugation and payload technologies. The BiTAC (Bispecific T-cell Activating Construct) platforms are designed to engage T-cells for targeted killing of tumor cells, with the ADC variant combining this mechanism with cytotoxic payload delivery. According to a Yahoo Finance report, these patent filings are a strategic move to protect the company's innovative technologies and establish a strong position in the competitive oncology landscape.

VERAXA is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats. This portfolio approach allows the company to pursue multiple mechanisms of action and target a broad range of cancer types. By advancing VXA-222 and securing intellectual property around its platforms, VERAXA is positioning itself as an emerging leader in the field of novel cancer therapies.

The company's focus on “AND-gate” logic in its ADC design is particularly noteworthy. Traditional ADCs rely on the expression of a single antigen on tumor cells, which can also be present on healthy tissues, leading to toxicity. By requiring the simultaneous recognition of two antigens, VXA-222 aims to achieve greater tumor selectivity. This approach could potentially expand the therapeutic window and enable the treatment of cancers that are currently difficult to target.

Looking ahead, the preclinical validation of VXA-222 will be critical in determining whether the candidate advances to clinical trials. Success in these studies would represent a major milestone for VERAXA, validating its technology platforms and potentially attracting partnerships or investment. The company's expanding IP portfolio further enhances its value proposition, as it protects the core innovations that underpin its pipeline.

For investors, this development signals that VERAXA is executing on its strategic plan, transitioning from discovery to development. The company's ability to integrate OmniAb's antibody binders with its own proprietary technologies demonstrates the effectiveness of its collaborative approach. As VERAXA continues to build its pipeline and protect its intellectual property, it is poised to make meaningful contributions to the field of cancer immunotherapy.

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.